
Efinopegdutide Produces Strong Histologic Responses in Phase 2b MASH Study
As reported on Business Wire, new data from Merck suggest that efinopegdutide, an investigational dual GLP-1/glucagon receptor agonist, may offer a promising new approach for
“We are focused on improving patient lives, increasing public awareness of liver disease, advancing liver transplantation and funding cutting-edge liver disease research – we’re working every day to help save lives. As the largest organization focused on all liver diseases, ALF provides trusted support, resources and education while advocating for public policy change and increased government funding for liver disease research on Capitol Hill. ALF serves as a beacon for the 100 million Americans affected by liver disease.”
Here is a list of conditions this partner raises awareness and advocacy for:

As reported on Business Wire, new data from Merck suggest that efinopegdutide, an investigational dual GLP-1/glucagon receptor agonist, may offer a promising new approach for

Editor’s Note: This article was written by Wayne Eskridge, founder of the Fatty Liver Foundation. When we are diagnosed with F4 MASH (cirrhosis) we are

As published in Sage Journals, researchers have developed an accessible, machine learning-driven histopathology workflow that enables quantitative evaluation of metabolic dysfunction-associated steatohepatitis (MASH) in laboratory

As reported on Bioengineer and ScienMag, a new spatial transcriptomics study has provided fresh insight into how different regions of the liver are remodeled during

Many people spend very little time contemplating their liver, often ignoring this critical organ until a major medical issue arises. In contrast, health culture in

As reported on BioSpace, AstraZeneca has entered a major artificial intelligence-focused research collaboration with biotechnology company insitro, committing up to $1.5 billion in potential payments
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
What best describes you when it comes to rare disease? (check all that apply)
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.